SAN FRANCISCO This year's edition of Transcatheter Cardiovascular Therapeutics isn't exactly swimming with regulatory personnel, but one of the more strategically important sessions took place yesterday morning, when regulators and industry met to discuss the current state of harmonization-by-doing (HBD) between FDA and Japan's Pharmaceuticals and Medical Devices Agency (PMDA). Read More
